LDA220Q-52 St. Jude Medical, Optisure™, Defibrillation lead 52 cm, Dual Shock, steroid-eluting, active fixation , Connector: DF4- LLHH

Description Optisure™ Models LDA220, LDA230, LDA210, LDA220Q, LDA230Q, LDA210Q, LDP220, LDP230, LDP220Q, and LDP230Q transvenous tachyarrhythmia leads are steroid-eluting, active or passive fixation leads, and are designed for long-term attachment to an implantable cardioverter defibrillator (ICD).

• All leads have two defibrillation electrodes except for models LDA210 and LDA210Q which have one.
• The leads provide true bipolar rate-sensing, pacing, and delivery of cardioversion/defibrillation shocks.
• Certain Optisure models and lead lengths have been tested for use in the MRI environment and are designated MR Conditional. 
• All models are designed for implantation with the distal tip positioned in the right ventricle.

For models LDA220, LDA230, LDA210, LDA220Q, LDA230Q, and LDA210Q, the tip incorporates an extendable/retractable helix for fixation in the ventricle.

• The retractable helix allows the electrical testing of possible lead positions prior to advancement of the fixation helix.
• The design of the tip aids visibility under fluoroscopy. For models LDP220, LDP230, LDP220Q, and LDP230Q, the tip of the lead has tines for fixation in the ventricle.
• The low profile, flat-wire defibrillation electrodes with silicone rubber backfilling are intended to preclude tissue ingrowth.

Models LDA220, LDA230, LDA210, LDA220Q, LDA230Q, LDP220, LDP230, LDP220Q, and LDP230Q are quadripolar leads and models LDA210 and LDA210Q are tripolar leads.

Portions of the lead body have an Optim™ (silicone polyurethane copolymer) insulation overlay. The lead body insulation tubing is Optim™ insulation and silicone rubber for long-term biocompatibility and biostability.

The lead body is treated with Fast-Pass™ coating to provide lubricity during lead implant.

After contact with body fluid, the tip electrode elutes dexamethasone sodium phosphate (DSP), a steroid. This minimizes tissue inflammation, which, in turn, is intended to reduce both acute and chronic pacing thresholds.

For models LDA220, LDA230, LDA210, LDA220Q, LDA230Q, and LDA210Q, the target dose of DSP in the monolithic controlled release device (MCRD) is 491 micrograms.

For models LDP220, LDP230, LDP220Q, and LDP230Q, the target dose of DSP in the MCRD is 324 micrograms and the target dose of DSP in the tip electrode coating is 121 micrograms. The total dose of DSP for these models is 445 micrograms